Home »

Ritter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities

LOS ANGELES, CA — (Marketwired) — 04/12/17 — Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR) (the "Company") today, April 12, 2017, announced that the U.S. Food and Drug Administration (FDA) has agreed to schedule an end of phase 2 meeting with the company which is expected to take place in the third quarter of 2017. The Company plans to discuss the results of its recently completed phase 2b/3 trial and phase 3 plans in preparation of a New Drug Application (NDA) submission of RP-G28 f

Analytics

© 2019 88Finance. All Rights Reserved. Log in - Copyright by LayerMedia


Blogverzeichnis - Blog Verzeichnis bloggerei.de Blog Top Liste - by TopBlogs.de